Malini Basu

Malini Basu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2023 in Genes & Diseases
Verified
Journal Article
Open access
SKSunny Kumar
Sunny Kumar
MCMouli Chatterjee
Mouli Chatterjee
PGPratyasha Ghosh
Pratyasha Ghosh
KGKirat K. Ganguly
Kirat K. Ganguly
MBMalini Basu
Malini Basu
MGMrinal Ghosh
Mrinal Ghosh
Maintaining the balance between eliciting immune responses against foreign proteins and tolerating self-proteins is crucial for maintenance of homeostasis. The functions of programmed death protein 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1) are to inhibit immune responses so that over-reacting immune cells does not cause any damage to its own body cells. However, cancer cells hijack this mechanism to attenuate immune cells functions and create an immunosuppressive environment that fuel their continuous growth and proliferation. Over the past few years’ rapid development in cancer immunotherapy has opened a new avenue in cancer treatment. Blockade of PD-1 and PD-L1 has become a potential strategy that rescue the functions of immune cells to fight against cancer with high efficacy. Initially, immune checkpoint monotherapies were not very successful, making breast cancer less immunogenic. Although, recent reports support the presence of tumor infiltrating lymphocytes (TILs) in breast cancer that make it favorable for PD-1/PD-L1 mediated immunotherapy, which is effective in PD-L1 positive patients. Recently, anti-PD-1 (pembrolizumab) and anti-PD-L1 (atezolizumab) gets FDA approval for breast cancer treatment and make PD-1/PD-L1 immunotherapy is meaningful for further research. Likewise, this article gathered understanding of PD-1 and PD-L1 in recent years, their signaling networks, interaction with other molecules, regulations of their expressions and functions in both normal and tumor tissue microenvironments are crucial to find and design therapeutic agents that block this pathway and improve the treatment efficacy. Additionally, authors collected and highlighted most of the important clinical trial reports on monotherapy and combination therapy.

31 December 2020 in Cells
Verified
Journal Article
Open access
PDF file
NDNeerajana Datta
Neerajana Datta
SCShrabastee Chakraborty
Shrabastee Chakraborty
MBMalini Basu
Malini Basu
MGMrinal Ghosh
Mrinal Ghosh
Cancer progression involves multiple genetic and epigenetic events, which involve gain-of-functions of oncogenes and loss-of-functions of tumor suppressor genes. Classical tumor suppressor genes are recessive in nature, anti-proliferative, and frequently found inactivated or mutated in cancers. However, extensive research over the last few years have elucidated that certain tumor suppressor genes do not conform to these standard definitions and might act as “double agents”, playing contrasting roles in vivo in cells, where either due to haploinsufficiency, epigenetic hypermethylation, or due to involvement with multiple genetic and oncogenic events, they play an enhanced proliferative role and facilitate the pathogenesis of cancer. This review discusses and highlights some of these exceptions; the genetic events, cellular contexts, and mechanisms by which four important tumor suppressors—pRb, PTEN, FOXO, and PML display their oncogenic potentials and pro-survival traits in cancer.

2 October 2022 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
SKSunny Kumar
Sunny Kumar
MBMalini Basu
Malini Basu
PGPratyasha Ghosh
Pratyasha Ghosh
AAAafreen Ansari
Aafreen Ansari
MGMrinal Ghosh
Mrinal Ghosh

1 July 2023 in Genes & Diseases
Verified
Journal Article
Open access
SKSunny Kumar
Sunny Kumar
MBMalini Basu
Malini Basu
PGPratyasha Ghosh
Pratyasha Ghosh
UPUttam Pal
Uttam Pal
MGMrinal Ghosh
Mrinal Ghosh
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes the complicated disease COVID-19. Clinicians are continuously facing huge problems in the treatment of patients, as COVID-19-specific drugs are not available, hence the principle of drug repurposing serves as a one-and-only hope. Globally, the repurposing of many drugs is underway; few of them are already approved by the regulatory bodies for their clinical use and most of them are in different phases of clinical trials. Here in this review, our main aim is to discuss in detail the up-to-date information on the target-based pharmacological classification of repurposed drugs, the potential mechanism of actions, and the current clinical trial status of various drugs which are under repurposing since early 2020. At last, we briefly proposed the probable pharmacological and therapeutic drug targets that may be preferred as a futuristic drug discovery approach in the development of effective medicines.

1 February 2023 in Epigenomics
Verified
Journal Article
Open access
MGMrinal Ghosh
Mrinal Ghosh
SKSunny Kumar
Sunny Kumar
KGKirat K Ganguly
Kirat K Ganguly
PGPratyay Ghosh
Pratyay Ghosh
STShaheda Tabassum
Shaheda Tabassum
MBMalini Basu
Malini Basu
The COVID-19 outbreak has created disaster globally, and mankind is yet to come in terms with combating this global menace. Amid this turmoil, immunocompromised individuals like cancer patients exh...